HYPERION sotatercept study has positive results, stops early

PHA Canada
Feb 10, 2025
1 min read

The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial hypertension reduced the risk of disease progression. The trial was stopped early so all patients in the trial, including those in the placebo arm, can benefit from sotatercept. Patients in the trial will be able to receive sotatercept through the ongoing SOTERIA extension study.

Study results have not yet been published.

Read the press release here

Recent Posts

Sotatercept might help treat portopulmonary hypertension

Patients with portopulmonary hypertension were not included in clinical trials for sotatercept. This case report found that sotatercept helped one patient with portopulmonary hypertension, who was the

Exercise is safe and effective for PH patients

Researchers conducted a meta-analysis, looking at 13 studies with about 700 participants in total with pulmonary hypertension (PH). They found that exercise improved 6-minute walk distance and was con

In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy pa

Comments